Minimal Invasive Oro-Dental Procedures – Recommendations For

Total Page:16

File Type:pdf, Size:1020Kb

Minimal Invasive Oro-Dental Procedures – Recommendations For PRACTICA MEDICALĂ Ref: Ro J Med Pract. 2018;13(4) CERCETARE ŞTIINȚIFICĂ DOI: 10.37897/RJMP.2018.4.6 Minimal invasive oro-dental procedures – recommendations for optimal care in children with haemophilia CS II Andrei KOZMA1,4, PhD, MMD, MDHC, CS Emilia URSU2, MD, Conf. Roxana OANCEA3, MD, PhD, Assist. Prof. Ana Maria Alexandra STANESCU5, MD, PhD, Prof. Margit SERBAN2,4*, MD, PhD, Assoc. Prof. Smaranda ARGHIRESCU3, MD, PhD 1“Alessandrescu-Rusescu” National Institute for Mother and Child Health, Bucharest 2“Louis Turcanu” Children`s Emergency Hospital, Timisoara, Romania 3“Victor Babes” University of Medicine and Pharmacy, Timişoara, Romania 4Romanian Academy of Medical Sciences 5"Carol Davila" University of Medicine and Pharmacy, Bucharest ABSTRACT Oral and dental treatments are an essential condition for a good quality of life for hemifiliacs. Hemophilia is a hereditary disease that is manifested in male subjects and consists in lifelong alteration of antihemorrhagic mechanisms. Clinical investigations show that a significant percentage of haemophiliacs are diagnosed with bleeding of the oral and periodontal mucosa during both prosthetic and dental morphology restoration maneuvers. Small dental surgery procedures such as anesthesia, extirpation of dental pulp and other surgical procedures require pre- and postoperative treatment with Factor VIII or factor IX. The authors present steps that are indicated to be performed before, during and after dental treatments that can cause bleedings in the oral cavity. The area and mode of use of alternative or complementary hemostatic therapy is also presented, as well as the precautions required during local anesthesia. In conclusion, it can be said that people with haemophilia or congenital bleeding tendencies are a priority group for dental and oral health care, since bleeding after dental treatment may cause severe or even fatal complications. Maintenance of a healthy mouth and prevention of dental problems is of great importance, not only to quality of life and nutrition, but also to avoid the dangers of surgery. Keywords: haemophilia, dental treatment, antihemorrhagic factors, local anesthetics Dental and oral health represent an impor- 1/50,000 males in haemophilia B. They are con- tant condition for a good quality of life. To reach sidered severe when plasma activity - for F VIII it can be a challenging process in persons with or IX is <1 IU/dl, moderate if it ranges between haemophilia (1-3). 1-5 IU/dl and mild if it is between 5-40IU/dl. Haemophilia and related disorders are a Clinical investigators, estimating the nature of group of inherited bleeding disorders character- symptoms which are leading to the diagnosis, ized by a life-long defect in the clotting mecha- reported that 14% of haemophiliacs and 30% of nism. Haemophilia A and B are defined by their cases with mild haemophilia were diagnosed deficiency in Factor VIII and IX , respectively. based on a significant oral or dental bleeding They are rare diseases with an estimated fre- (3,4). quency of 1/10,000 males in haemophilia A and Corresponding author: Prof. Dr. Margit Serban, „Louis Turcanu” Children`s Emergency Hospital, Timişoara, Romania E-mail: [email protected] PRACTICA MEDICALÅ – VOL. 13, NR. 4(61), AN 2018 267 PRACTICA MEDICALÅ – VOL. 13, NR. 4(61), AN 2018 TABLE 1. Average age for tooth eruption TABLE 2. The need of hemostatic replacement therapy Deciduous (Primary) Teeth LOCAL ANESTHETIC TECHNIQUES Age (in months) NO HEMOSTATIC COVER HEMOSTATIC COVER Upper Lower REQUIRED REQUIRED 1.Central incisors 8-13 6-10 Bucal infiltration Inferior dental (ID) 2.Lateral incisors 8-13 10-16 Intra-papillary injections block Intra-ligamentary injections Lingual infiltration 3.Canines (cuspids) 16-23 16-23 4.First molars 13-19 13-19 In the following we will present some recom- 5.Second molars 25-33 23-31 mendations to be respected in our medical ac- Permanent Teeth tivity (6-9). Age (in years) Upper Lower First Steps – before stomatological treatment 1.Central incisors 7-8 6-7 2.Lateral incisors 8-9 7-8 • informing the dentist that the patient has 3.Canines (cuspids) 11-12 9-10 haemophilia before beginning any procedu- 4.First premolars (bicuspids) 10-11 10-12 re 5.Second premolars (bicuspids) 10-12 11-12 • people with bleeding disorders need close 6.First molars 6-7 6-7 cooperation between their physician and 7.Second molars 12-13 11-13 their dentist to receive safe, comprehensive 8.Third molars 17-21 17-21 dental care • in order to help the dentist for planing a cor- Physiological events (decidual or permanent rect course of treatment, it is important to tooth eruption, mobile tooth roots and natural- provide the following information ly falling out of decidual tooth) (Tab.1), but – the type and severity of hemophilia moreover medical interventions (treatment of – the medications used dental caries or of periodontal damage, dental – whether pre-treatment with factor con- plaque correction) or invasive procedures (tooth centrate, nasal desmopressin or an antifi- extraction, suturing of wounds or incisions, lo- brinolytic agent (tranexamic acid or epsi- cal anaestesia, fixed or removable orthodontic lon amino caproic acid) is required appliances, endodontic pulpectomy, anesthesia – contact information about the Hae- with inferior alveolar dental block or lingual in- mophilia Treatment Center filtration) can cause bleedings, that persist for – whether there are: days or weeks, generating life - threatening - inhibitors anti-FVIII or FIX complications, which can be stopped only with - infectious diseases, such as hepatitis, specific, disease - adapted measures. They can HIV infection occur even in asymptomatic haemophiliacs with - previous joint replacement moderate or mild disease (4,5). - venous access device (port) Taking all these into consideration, it is obvi- • dental appointments of children with blee- ous that successful protocols can only be the ding disorders, as well as education in pre- result of cooperation between dentist and he- ventive dentistry for children and caregivers, matologist , in frame of a comprehensive care should be started when the baby teeth begin team and center. The purpose of such guide- to erupt lines is the safety of the group of patients, vul- • comprehensive dental assessment is needed nerable from the point of view of their hemo- at the age of about 12 or 13, to plan for the stasis, presenting the risky burden of very rare future and to decide how best to forestall di- disorders, with unmet and not generally known fficulties resulting from overcrowding or mi- needs (Table 2 and Table 3). splaced third molars or other teeth TABLE 3. Suggested plasma factor peak level and duration of administration of coagulation factor concentrates in minor invasive interventions Haemophilia A Haemophilia B Type of bleeding Desired Factor Durati on Desired Factor Durati on level UI/kg dosage UI/kg days level UI/dl dosage UI/kg days Pre-operati ve 50-100 25-50 1 50-100 50-100 Post-operati ve 30-80 15-40 1-5 30-80 30-80 1-5 268 PRACTICA MEDICALÅ – VOL. 13, NR. 4(61), AN 2018 • for those with severe haemophilia, factor re- thrombocytopenia, which can worsen the placement is necessary before scaling, sur- bleeding tendency gery or regional block injections. For exam- • hepatitis C is extremely common in people ple, a dose of 50 international units per with haemophilia, can be associated with a kilogram of body weight (IU/ kg) of factor VIII prolonged prothrombin time or INR (Interna- is desirable before a tooth extraction in a tional Normalized Ratio) and thrombocyto- person with haemophilia A; in haemophilia penia; in such cases, bleeding cannot be pre- B, a dose of 100 IU/ kg of factor IX is required vented with factor VIII (or IX); fresh frozen (Table 3) plasma may be required. General tips during the dental treatment of TABLE 4. Alternative or adjunctive hemostatic therapy haemophilic pacients Medicati on Dosage Route • fillings, scalling, root canal and all cosmetic Desmopressin (DDAVP) 0,3 μg/ kg IV, SC and preventative care can be carried out ro- Tranexamic acid 25mg/ kg x 3/ d IV, oral, topic utinely on patients with mild bleeding disor- Epsilon-amino-caproic 50mg/ kg x 4/ d IV, oral, topic acid (EACA) ders • however, care should be taken with the soft Areas of concerns tissues, especially the use of impression trays, aspirators and x-ray films in the floor of • extractions and surgery the mouth • gingival surgery/ deep root planning and • for people with mild or moderate haemophi- • implant placement , all pose a bleeding risk, lia, non-surgical dental treatment can be car- even in patients with mild haemophilia; so, it ried out under antifibrinolytic cover, but a is essential that these procedures are carried hematologist must be consulted before out with the necessary pre-operative special other procedures are done (Table 4) measures such as factor replacement, DDAVP • for people with mild haemophilia A (with or Cyclokapron tablets factor VIII > 10%) and most people with VWD • deep injections, surgical procedures particu- (type 1), scaling and some minor surgery larly those involving bone (extractions, den- may be possible under desmopressin tal implants) and regional local anesthetic (DDAVP) cover; however, DDAVP is not effec- blocks should be avoided, where possible, as tive in haemophilia B (even mild cases) as it they may start a bleeding crisis does not boost factor IX levels • local use of fibrin glue and swish-and- • tranexamic acid used tropically significantly swallow rinses
Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Systematic Review of Tranexamic Acid Adverse Reactions
    arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Calapai et al., J Pharmacovigilance 2015, 3:4 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000171 Review Open Access Systematic Review of Tranexamic Acid Adverse Reactions Gioacchino Calapai2*, Sebastiano Gangemi1, Carmen Mannucci2, Paola Lucia Minciullo1, Marco Casciaro1, Fabrizio Calapai3, Maria Righi4 and Michele Navarra5 1Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Italy 2Department of Clinical and Experimental Medicine, University of Messina, Italy 3Centro Studi Pharma.Ca, Messina, Italy 4Department of Biomedical Sciences and Morphological and Functional Images, University of Messina, Italy 5Department of Drug Sciences and Health Products, University of Messina, Italy *Corresponding author: Gioacchino Calapai, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 5, 98125 Messina, Italy, Tel: +39 090 2213646; Fax: +39 090 221; E-mail: [email protected] Received date: July 06, 2015; Accepted date: July 14, 2015; Published date: July 20, 2015 Copyright: © 2015 Calapai G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background Tranexamic acid is a synthetic lysine derivate that exerts its antifibrinolytic effect by reversible blocking lysine binding sites on plasminogen preventing fibrin degradation. It is widely used for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Aim The aim of our work was to review the literature regarding the best evidence on tranexamic adverse reactions and to describe them according to the apparatus involved.
    [Show full text]
  • The Phytochemistry of Cherokee Aromatic Medicinal Plants
    medicines Review The Phytochemistry of Cherokee Aromatic Medicinal Plants William N. Setzer 1,2 1 Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA; [email protected]; Tel.: +1-256-824-6519 2 Aromatic Plant Research Center, 230 N 1200 E, Suite 102, Lehi, UT 84043, USA Received: 25 October 2018; Accepted: 8 November 2018; Published: 12 November 2018 Abstract: Background: Native Americans have had a rich ethnobotanical heritage for treating diseases, ailments, and injuries. Cherokee traditional medicine has provided numerous aromatic and medicinal plants that not only were used by the Cherokee people, but were also adopted for use by European settlers in North America. Methods: The aim of this review was to examine the Cherokee ethnobotanical literature and the published phytochemical investigations on Cherokee medicinal plants and to correlate phytochemical constituents with traditional uses and biological activities. Results: Several Cherokee medicinal plants are still in use today as herbal medicines, including, for example, yarrow (Achillea millefolium), black cohosh (Cimicifuga racemosa), American ginseng (Panax quinquefolius), and blue skullcap (Scutellaria lateriflora). This review presents a summary of the traditional uses, phytochemical constituents, and biological activities of Cherokee aromatic and medicinal plants. Conclusions: The list is not complete, however, as there is still much work needed in phytochemical investigation and pharmacological evaluation of many traditional herbal medicines. Keywords: Cherokee; Native American; traditional herbal medicine; chemical constituents; pharmacology 1. Introduction Natural products have been an important source of medicinal agents throughout history and modern medicine continues to rely on traditional knowledge for treatment of human maladies [1]. Traditional medicines such as Traditional Chinese Medicine [2], Ayurvedic [3], and medicinal plants from Latin America [4] have proven to be rich resources of biologically active compounds and potential new drugs.
    [Show full text]
  • Aon Exchange Formulary
    GEISINGER HEALTH PLAN 2021 member formulary List of covered drugs AON Exchange medication benefit General Formulary Information This formulary is applicable to the AON Exchange Prescription Medication Benefit plans offered by Geisinger Health Plan, Geisinger Choice PPO and Geisinger Health Options. We encourage you to contact our Pharmacy Customer Service Team if you have any questions about this information or the type of benefit in which you are enrolled. Also, please refer to your benefit documents, as formulary exclusions may differ based on the specific benefit. This formulary represents the Aon Exchange Prescription Medication benefit. This formulary was designed to be a useful tool if you have prescription medication coverage. It lists the medications covered by your plan. Medications are listed in this formulary by medication category; individual medications can be looked up by using the index at the back. Please note that you can also view the formulary online at www.geisinger.org/health-plan. Pharmacy Customer Service Team Contact Information Telephone: (800) 988-4861 or (570)-271-5673; TDD/TTY 711 Fax: 570-300-2122 Mailing address: Geisinger Health Plan Pharmacy Department Internal Mail Code 24-10 100 North Academy Avenue Danville, PA 17822 AON Exchange Benefit The Aon Exchange benefit assigns each prescription medication to one of three different tiers, each representing a set copay amount. The copay amount will depend on your prescription medication rider. Additional medications, other than those included in this formulary, may be covered under the Triple Choice benefit. The definitions of the copay levels are listed below: • Tier 1 - Includes most generic medications and has the lowest copayment.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification (2012).Pdf
    AHFS Pharmacologic-Therapeutic Classification 4:00 Antihistamine Drugs 4:04 First Generation Antihistamines 4:04.04 Ethanolamine Derivatives 4:04.08 Ethylenediamine Derivatives 4:04.12 Phenothiazine Derivatives 4:04.16 Piperazine Derivatives 4:04.20 Propylamine Derivatives 4:04.92 Miscellaneous Derivatives 4:08 Second Generation Antihistamines 4:92 Other Antihistamines* 8:00 Anti-infective Agents 8:08 Anthelmintics 8:12 Antibacterials 8:12.02 Aminoglycosides 8:12.06 Cephalosporins 8:12.06.04 First Generation Cephalosporins 8:12.06.08 Second Generation Cephalosporins 8:12.06.12 Third Generation Cephalosporins 8:12.06.16 Fourth Generation Cephalosporins 8:12.07 Miscellaneous -Lactams 8:12.07.04 Carbacephems 8:12.07.08 Carbapenems 8:12.07.12 Cephamycins 8:12.07.16 Monobactams 8:12.08 Chloramphenicol 8:12.12 Macrolides 8:12.12.04 Erythromycins 8:12.12.12 Ketolides 8:12.12.92 Other Macrolides 8:12.16 Penicillins 8:12.16.04 Natural Penicillins 8:12.16.08 Aminopenicillins 8:12.16.12 Penicillinase-resistant Penicillins 8:12.16.16 Extended-spectrum Penicillins 8:12.18 Quinolones 8:12.20 Sulfonamides 8:12.24 Tetracyclines 8:12.24.12 Glycylcyclines 8:12.28 Antibacterials, Miscellaneous 8:12.28.04 Aminocyclitols 8:12.28.08 Bacitracins 8:12.28.12 Cyclic Lipopeptides 8:12.28.16 Glycopeptides 8:12.28.20 Lincomycins 8:12.28.24 Oxazolidinones 8:12.28.28 Polymyxins 8:12.28.30 Rifamycins 8:12.28.32 Streptogramins 8:12.28.92 Other Miscellaneous Antibacterials* 8:14 Antifungals 8:14.04 Allylamines 8:14.08 Azoles 8:14.16 Echinocandins 8:14.28 Polyenes 8:14.32
    [Show full text]
  • Ankaferd Blood Stopper Is More Effective Than Adrenaline Plus Lidocaine and Gelatin Foam in the Treatment of Epistaxis in Rabbits Mehmet Kelles, MD1; M
    Current Therapeutic Research VOLUME ,NUMBER ,OCTOBER Ankaferd Blood Stopper Is More Effective Than Adrenaline Plus Lidocaine and Gelatin Foam in the Treatment of Epistaxis in Rabbits Mehmet Kelles, MD1; M. Tayyar Kalcioglu, MD1; Emine Samdanci, MD2; Erol Selimoglu, MD1; Mustafa Iraz, MD3; Murat Cem Miman, MD4; and Ibrahim C. Haznedaroglu, MD5 1Department of Otorhinolaryngology, Inonu University, Malatya, Turkey; 2Department of Pathology, Inonu University, Malatya, Turkey; 3Department of Pharmacology, Bezmialem Vakif University, Istanbul, Turkey; 4Department of Otorhinolaryngology, Kocatepe University, Afyon, Turkey; and 5Department of Hematology, Hacettepe University, Ankara, Turkey ABSTRACT Background: Epistaxis is an important emergency that can sometimes be life threatening without effective intervention. Persistent and recurrent bleeding can lead to aspiration, hypotension, hypoxia, or even severe and mortal cardiovascular com- plications. Providing prompt hemostasis is important, and the hemostatic method used must be easily and locally applicable, efficient, and inexpensive. Objective: The aim of this study was to assess the hemostatic efficacy of Ankaferd Blood Stopper (ABS) in an experimental epistaxis model and to determine the histopathologic alterations with topical ABS application. Methods: Twenty-eight New Zealand rabbits were evaluated in 4 study groups. Topical ABS, gelatin foam (GF), adrenalin ϩ lidocaine (AL), and serum physiologic as negative control (C) were applied to the animals for controlling epistaxis. The bleeding was generated with a standard mucosal incision in all groups. Cotton pieces soaked with ABS, AL, C, and GF were applied to the nasal bleeding area. Time of hemostasis was recorded. Tissue samples were obtained after hemostasis for histopathologic examination. The samples were stained with hematoxylin and eosin (HE) and phosphotungstic acid hematoxylin (PTAH) and were examined under a light microscope.
    [Show full text]
  • Comparison Between the Clot-Protecting Activity of a Mutant Plasminogen Activator Inhibitor-1 with a Very Long Half-Life and 6-Aminocaproic Acid
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2339-2343, 2015 Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid DANIEL GLENN KINDELL1, RICK WAYNE KECK1 and JERZY JANKUN1-3 1Urology Research Center, Department of Urology, University of Toledo, Health Science Campus, Toledo, OH 43614, USA; 2Protein Research Chair, Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia; 3Department of Clinical Nutrition, Medical University of Gdańsk, Gdańsk, Pomerania 80‑211, Poland Received August 20, 2014; Accepted November 17, 2014 DOI: 10.3892/etm.2015.2399 Abstract. Plasminogen activator inhibitor (PAI)-1 is a serpin Introduction glycoprotein that can stabilize blood clots by inhibiting fibrino- lysis. However, wild-type PAI-1 has the disadvantage of a short Coagulation, the formation of a clot, is an essential process half-life of ~2 h. A very long half-life (VLHL) PAI-1 mutant in the maintenance of homeostasis under normal condi- was developed previously with an active-form half-life of tions and during traumatic events. Numerous agents are >700 h, making it a possible candidate for use in hemorrhagic used to initiate clotting and prevent uncontrolled bleeding. therapy. Current treatments for mitigating hemorrhage, other However, only a few agents, with limited efficacy, are used than inducers of blood clotting, are limited to lysine analog anti- in clinical practice to protect formed clots against premature fibrinolytics, including 6‑aminocaproic acid and tranexamic lysis (1,2). The crosslinked polymer, fibrin, is dissolved into acid. VLHL PAI-1 has been previously demonstrated to limit fibrin degradation products by plasmin.
    [Show full text]
  • Core Curriculum for Iv Therapy
    DIRECT ENTRY MIDWIFERY LEGEND DRUGS AND DEVICES INITIAL EDUCATION Oregon Health Licensing Agency Board of Direct Entry Midwifery 700 Summer Street N.E., Suite #320 Salem, Oregon 97301-1287 (503) 378 - 8667 Fax: (503) 370-9004 E-mail: [email protected] LEGEND DRUGS AND DEVICES INITIAL EDUCATION 40 hours The Initial Legend Drugs and Devices Education Program shall consist of 40 total hours of instruction in the following: 8 hours - Pharmacology; 4 hours - Administration of medications through injection; 4 hours - Treatment of shock; 10 hours – I.V. Therapy; 4 hours - Neonatal resuscitation specific to out of hospital birth and 10 hours - Suturing. See core curriculum for learning objectives and other details. Course / Description Hours Required PHARMACOLOGY: 8 hours ADMINISTRATION OF MEDICATIONS THROUGH INJECTION: 4 hours TREATMENT OF SHOCK: 4 hours I.V. THERAPY: 10 hours NEONATAL RESUSCITATION: 4 hours SUTURING: 10 hours TOTAL HOURS: 40 HOURS In the course of study the candidate shall receive theory instruction, classroom instructor demonstrations and/or guided practical experience under the supervision of the authorized provider. The amounts of time a candidate devotes to theory and practice are flexible provided the minimum hour requirements listed above are met. In addition to the forty hours of instruction, the course must include assessment of theory and skills. 2 CORE CURRICULUM FOR PHARMACOLOGY – 1 of 2 Objectives Dosage Guidelines Standards for Resources Instructors Define a drug Synthetic Oxytocin (Pitocin, Licensed Current Define"legend drugs and Syntocin & Generic) IM: 10U Pharmacist Edition of the devices" Explain OAR’s (1ml), may repeat at 2 hour (not limited following: concerning legend drugs and intervals as necessary to to Oregon Pharmacology devices Define and explain maintain uterine tone.
    [Show full text]
  • Antithrombotic Prophylaxis for Surgery
    ARTICLE Platelet Biology & its Disorders Antithrombotic prophylaxis for Ferrata Storti Foundation surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study Francesco Paciullo,1 Loredana Bury,1 Patrizia Noris,2 Emanuela Falcinelli,1 Federica Melazzini,2 Sara Orsini,1 Carlo Zaninetti,2,3 Rezan Abdul-Kadir,4 Deborah Obeng-Tuudah,4 Paula G. Heller,5,6 Ana C. Glembotsky,5,6 Fabrizio Fabris,7 Jose Haematologica 2020 Rivera,8 Maria Luisa Lozano,8 Nora Butta,9 Remi Favier,10 Ana Rosa Cid,11 Volume 105(7):1948-1956 Marc Fouassier,12 Gian Marco Podda,13 Cristina Santoro,14 Elvira Grandone,15,16 Yvonne Henskens,17 Paquita Nurden,8 Barbara Zieger,19 Adam Cuker,20 Katrien Devreese,21 Alberto Tosetto,22 Erica De Candia,23,24 Arnaud Dupuis,25 Koji Miyazaki,26 Maha Othman27 and Paolo Gresele1 1Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; 2Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy; 3PhD program in Experimental Medicine, University of Pavia, Pavia, Italy; 4Haemophilia Centre and Haemostasis Unit, The Royal Free Foundation Hospital and University College London, London, UK; 5Hematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina; 6CONICET, Universidad de Buenos Aires, Instituto de Investigaciones Médicas - IDIM-, Buenos Aires, Argentina; 7Clinica Medica 1 - Medicina Interna CLOPD, Dipartimento Assistenziale
    [Show full text]
  • Pharmacology Cito
    Pharmacology Cito 5 Read: it is important! Dear future physicians and pharmaceutists! The scientific and pedagogical staff of the Pharmacology department of the National University of Pharmacy (Kharkiv) presents a new textbook "Pharmacology – Cito!" to you. We want to change the myth that it is impossible to learn pharmacology quickly and qualitatively. The textbook "Pharmacology – Cito!" is published for those, who have decided to connect his or her profession with medicines, but think that a great amount of the information in pharmacology is hard to learn. Taking this fact into account we have decided to help those, who wish to master pharmacology in logical, fast - "Cito!"- version. Not be afraid of pharmacology! The 40-year experience of teaching pharmacology testifies that for the last 10-15 years a tendency of reducing the amount of classroom hours in pharmacology because of increasing the amount of the individual work is being observed. However, because of the lack of time and the constant increasing volume of information in pharmacology, everyone has not enough time to master it soundly and qualitatively. This textbook trains future pharmaceutists and physicians in the pharmacological logic, i.e. knowing the mechanisms of drug action one can understand their pharmacodynamics, naturally, on the basis of pharmacodynamics one can find logically the indications to their application and from their side effects the contraindications can be seen. The information about the peculiarities of medicines has been generalized and given as a pharmacological ―face‖ in tables. The volume of this textbook in pharmacology is sufficient for acquiring the confidence in the opportunity of the further improving of knowledge in this discipline, which is important for a physician and a pharmaceutist.
    [Show full text]
  • Pharmacology
    STATE ESTABLISHMENT «DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE» V.I. MAMCHUR, V.I. OPRYSHKO, А.А. NEFEDOV, A.E. LIEVYKH, E.V.KHOMIAK PHARMACOLOGY WORKBOOK FOR PRACTICAL CLASSES FOR FOREIGN STUDENTS STOMATOLOGY DEPARTMENT DNEPROPETROVSK - 2016 2 UDC: 378.180.6:61:615(075.5) Pharmacology. Workbook for practical classes for foreign stomatology students / V.Y. Mamchur, V.I. Opryshko, A.A. Nefedov. - Dnepropetrovsk, 2016. – 186 p. Reviewed by: N.I. Voloshchuk - MD, Professor of Pharmacology "Vinnitsa N.I. Pirogov National Medical University.‖ L.V. Savchenkova – Doctor of Medicine, Professor, Head of the Department of Clinical Pharmacology, State Establishment ―Lugansk state medical university‖ E.A. Podpletnyaya – Doctor of Pharmacy, Professor, Head of the Department of General and Clinical Pharmacy, State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ Approved and recommended for publication by the CMC of State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ (protocol №3 from 25.12.2012). The educational tutorial contains materials for practical classes and final module control on Pharmacology. The tutorial was prepared to improve self-learning of Pharmacology and optimization of practical classes. It contains questions for self-study for practical classes and final module control, prescription tasks, pharmacological terms that students must know in a particular topic, medical forms of main drugs, multiple choice questions (tests) for self- control, basic and additional references. This tutorial is also a student workbook that provides the entire scope of student’s work during Pharmacology course according to the credit-modular system. The tutorial was drawn up in accordance with the working program on Pharmacology approved by CMC of SE ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ on the basis of the standard program on Pharmacology for stomatology students of III - IV levels of accreditation in the specialties Stomatology – 7.110105, Kiev 2011.
    [Show full text]
  • Xyntha® Xyntha® Solofuse™
    PRODUCT MONOGRAPH Xyntha® Lyophilized Powder for Reconstitution in a Vial 250, 500, 1000, or 2000 IU in single-use vials and one pre-filled diluent syringe containing 4 mL 0.9% Sodium Chloride for reconstitution* and Xyntha® Solofuse™ Lyophilized Powder for Reconstitution in a Prefilled Dual-Chamber Syringe 250, 500, 1000, 2000, or 3000 IU and 4 mL 0.9 % Sodium Chloride solution for reconstitution in a prefilled dual-chamber syringe Antihemophilic Factor (Recombinant) [BDDrFVIII] For Intravenous Injection Antihemorrhagic Blood Coagulation Factor VIII ®T.M. Wyeth LLC Date of Revision: 28 April 2016 Pfizer Canada Inc., Licensee 17,300 Trans-Canada Highway Kirkland, Quebec Date of Approval: May 11, 2016 H9J 2M5 Submission Control Number: 191983 ©Pfizer Canada Inc. TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ......................................................................................................6 DRUG INTERACTIONS ......................................................................................................9
    [Show full text]